This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

LUX-Lung 3 clinical data1
XOVOLTIB® demonstrated superior 1st-line PFS versus pemetrexed/cisplatin independent of EGFR mutational subgroup1

LUX-Lung 3 (del19/L858R): PFS by independent review (primary endpoint)

  • In patients with common mutations, median PFS was 13.6 and 6.9 months for XOVOLTIB® and pemetrexed/cisplatin, respectively (HR=0.47; 95% CI, 0.34–0.65; P<0.001)1
  • 42% reduction in relative risk of death or tumour progression in the ITT population (HR=0.58; P<0.001)1

CI=confidence interval; EGFR M+=epidermal growth factor receptor mutation positive; HR=hazard ratio; ITT=intention-to-treat; PFS=progression-free survival.

LUX-Lung 6 clinical data2
XOVOLTIB® demonstrated superior 1st-line PFS versus gemcitabine/cisplatin, consistent across all subgroups, including mutation type2

LUX-Lung 6: PFS by independent review (primary endpoint)

  •  72% reduction in relative risk of death or tumour progression in the XOVOLTIB® group (HR=0.28; P<0.0001)2

CI=confidence interval; EGFR M+=epidermal growth factor receptor mutation positive; HR=hazard ratio; ITT=intention-to-treat; PFS=progression-free survival.

You may be interested in: 

Is this information compelling to you?

References

  1. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.
  2. Wu YL et al. Lancet Oncol. 2014;15(2):213-222.
  1. [1] Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.

  2. [2] Wu YL et al. Lancet Oncol. 2014;15(2):213-222.

  3. [3] Yang JC et al. Lancet Oncol. 2015;16(2):141-151.

  4. [4] Park K et al. Lancet Oncol. 2016;17(5):577-589.

  5. [5] Soria JC et al. Lancet Oncol. 2015;16(8):897-907.

  6. [6] Solca F et al. J Pharmacol Exp Ther. 2012;343(2):342-350.

  7. [7] Yang JC et al. J Clin Oncol. 2013;31(27):3342-3350.

  8. [8] Hirsch V et al. Poster #369 presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA; 3-7 June 2016.

  9. [9] Yang JCH et al. Ann Oncol. 2016;27(11):2103-2110.

  10. [10] Schuler M et al. J Thorac Oncol. 2016;11(3):380-390.

  11. [11] Paz-Arez L et al. Ann Oncol. 2017; 28(2):270-277

  12. [12] XOVOLTIB® Local pack insert version dated 21st July 2017

In case you come across any adverse events related to our products, please report it to PV team immediately.
Phone: +91 9819241697
Email: PV_local_India@boehringer-ingelheim.com

For any query on Boehringer Ingelheim India's product or therapy area, kindly contact
Phone: 1800227887
Email: medical.query.mum@boehringer-ingelheim.com

Back to top